Ausgabe 2/2023
Inhalt (10 Artikel)
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis
Adam Ioannou, Marianna Fontana, Julian D. Gillmore
Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines
Bingming Ou, Ying Yang, Haihui Lv, Xin Lin, Minyu Zhang
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context
Maximilian Ruschig, Andrea L. J. Marschall
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis
HyeJung Na, Sun-Hong Kwon, Kyung-Hwa Son, Youngsuk Baek, Jiye Kim, Eui-Kyung Lee
Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia
László Lorenzovici, László Szilberhorn, Szabolcs Farkas-Ráduly, Andrea Ildiko Gasparik, Andreea Mihaela Precup, Adél Gyöngyvér Nagy, Carsten Utoft Niemann, Tero Aittokallio, Zoltán Kaló, Marcell Csanádi
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Kevin Klein, Mümün Gencoglu, Jens Heisterberg, Virginia Acha, Pieter Stolk
Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study
Sun-Kyung Lee, Kichul Shin, Ju-Yang Jung, Chang-Hee Suh, Ji-Won Kim, Hyoun-Ah Kim
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
Huiping Li, Yan Huang, Zhendong Chen, Aiping Zeng, Helong Zhang, Yan Yu, Shihong Wei, Qingshan Li, Xiaojia Wang, Xiangcai Wang, Xiuwen Wang, Runxiang Yang, Xiumei Dai, Minghong Bi, Tao Sun, Qingyuan Zhang, Cuicui Han, Yujie Li, Xiaoyan Kang, Yaxin Liu, Li Zhang
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
JongAh Joanne Lee, Nayoung Lee, Young Jun Seo, Ilkoo Kim